Research agenda
| Topics | Specific questions |
|---|---|
| Composite activity measures (mainly PsA and peripheral SpA) | Validation where needed, definition of disease activity states and response categories |
| Remission definition | Is it important that all clinical domains of axial SpA, peripheral SpA or PsA are in remission or is it sufficient to define some of them? |
| Treatment target | Is there a difference in long-term outcome when comparing remission with low disease activity? |
| Activity and damage | What is the progression of joint damage in different disease activity states in PsA? |
| Disease duration | Are there differences in responsiveness and thus differences in attaining certain targets with different disease duration in PsA? |
| Treatment to target | There is a need to design therapeutic trials that compare steered therapy aiming at remission or low disease activity with non-steered treatment (like TICORA)88 |
| Axial involvement in PsA | Do spinal and peripheral involvements respond similarly or differently? |
| Enthesitis, dactylitis | More data need to be attained on the response of dactylitis or enthesitis to different therapies |
| Care by rheumatologist | Is care of axial SpA, peripheral SpA or PsA by a rheumatologist advantageous for outcomes when compared with care by non-rheumatologists? |
| Maintenance of response | How can response be maintained? Can the dose of the therapy employed be reduced or the interval of applications be expanded and outcome maintained? |
| Patient | Is outcome different when patients are informed in a structured way when compared with more general means of information? |
PsA, psoriatic arthritis; SpA, Spondyloarthritis.